Controversia sobre el uso de Aducanumabe® en el tratamiento del Alzheimer

João Paulo Camelo Menezes; Francisco Jeci de Holanda

João Paulo Camelo Menezes UniEP - Unidad de Enseñanza e Investigación. Brasil
Francisco Jeci de Holanda UniEP - Unidad de Enseñanza e Investigación. Brasil

Palabras clave: Alzheimer, Tratamiento, Farmacología

Resumen

El desarrollo de métodos modernos de investigación y diagnóstico abre la posibilidad de una detección rápida de diversas enfermedades, el uso de terapias dirigidas y mayores perspectivas de rehabilitación. Sin embargo, en el caso de trastornos neurológicos, esta producción no se acelera. El problema surge de la naturaleza multifactorial y compleja de la mayoría de los trastornos. Una de las enfermedades neurológicas más estudiadas es la enfermedad de Alzheimer (EA) [Fragmento de texto].

Bibliografía

1. Arndt, Joseph W.; Qian, Fang; Smith, Benjamin A; Quan, Chao et al. Structural and kinetic basis for the selectivity of aducan-umab for aggregated forms of amyloid-β. Sci Rep. 2018; 8: 1-16. https://nature.com/articles/s41598-018-24501-0.
2. Decourt, Boris; Boumelhem, Fadel; Pope 3rd, Evans D.; Shi, Jiong; Mari, Zoltan; Noel Sabbagh, Marwan. Critical Appraisal of Amyloid Lowering Agents in AD. Neurol Neurosc Rep. 2021; 21: 39. https://doi.org/10.1007/s11910-021-01125-y.
3. Delanogare, Eslen; Flores, Douglas; de Souza, Raul Marin; de Souza, Letícia; Luiz Gasnhar Moreira, Eduardo. Hipótese ami-loide e o tratamento da doença de Alzheimer: revisão dos estudos clínicos realizados. Vittalle Rev Ciênc Saúde. 2019; 31: 84-106. https://doi.org/10.14295/vittalle.v31i1.8395.
4. Esang, Michael; Gupta, Mayank. Aducanumab as a Novel Treatment for Alzheimer's Disease: A Decade of Hope, Controver-sies, and the Future. Cureus. 2021; 13: e17591. https://doi.org/10.7759/cureus.17591.
5. Fleming, Richard; Zeisel, John; Bennett B Arch, Kirsty. World Alzheimer Report 2020. Design Dignity Dementia: dementia-related design and the built environment. v. 1. London: Alzheimer’s Disease International. 2020; https://alzint.org/resource/world-alzheimer-report-2020.
6. Frölich, Lutz; Hausner, Lucrezia. Disease-modifying treatment approaches for Alzheimer's disease. Der Nervenarzt. 2021; 92:1239-48. https://doi.org/10.1007/s00115-021-01222-w.
7. Jeremic, Danko; Jiménez-Díaz, Lydia; Navarro-López, Juan D. Past, present and future of therapeutic strategies against amy-loid-β peptides in Alzheimer's disease: a systematic review. Ageing Res Rev. 2021; 72:101496. https://doi.org/10.1016/j.arr.2021.101496.
8. Lowe, S. L.; Duggan Evans, C.; Shcherbinin, S; Cheng, Y-J et al. Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. J Prevent Alzheimer Dis. 2021; 8:414-24. https://doi.org/10.14283/jpad.2021.56.
9. Mintun, Mark A.; Lo, Albert C.; Duggan Evans, Cynthia; Wessels, Alette M. et al. Donanemab in early Alzheimer’s disease. New Eng J Med. 2021; 384: 1691-704. https://doi.org/10.1056/NEJMoa2100708.
10. Jordy Sant’Ana, Natalia; Henrique Garcia Filho, Paulo; Rios Mendonça, Roberta; Kamada, Márcio. Terapia antiamiloide: uma nova estratégia para tratamento da doença de Alzheimer. Rev Soc Bras Clín Méd 2018;6:127-31. https://pesquisa.bvsalud.org/portal/resource/pt/biblio-913376.
11. Tolar, Martin.; Hey, John; Power, Aidan; Abushakra, Susan. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Patho-genesis and Represent a Clinically Validated Target for Slowing Disease Progression. Inter J Mol Sci 2021; 22:6355. https://doi.org/10.3390/ijms22126355.
12. Tousi, Babak; Noel Sabbagh, Marwan. A Time of Transition Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies. Neurol Ther. 2021; 1-5. https://doi.org/10.1007/s40120-021-00286-9.
13. Walsh, Sebastian; Merrick, Richard; Milne, Richard; Brayne, Carol. Aducanumab for Alzheimer's disease? BMJ 2021; 374: 1682. https://doi.org/10.1136/bmj.n1682.
14. Weiner, Michael W.; Aisen, P. S.; Beckett, L. A.; Green, R. C. et al. How Will Aducanumab Approval Impact AD Research? J Prevent Alzheimer Dis. 2021; 8: 391-2. https://doi.org/10.14283/jpad.2021.46.
15. Yu, Tien-Wey; Lane, Hsien-Yuan, Lin, Chieh-Hsin. Novel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review. Inter J Mol Sci. 2021; 22:8208. https://doi.org/10.3390/ijms22158208.